Expert: Potential Surufatinib FDA Approval for Neuroendocrine Tumors Is "Really Exciting"

Video

Surufatinib targets both the VEGF receptor and the CSF1R receptor, which is a unique mechanism of action.

In an interview with Pharmacy Times about her presentation at the North American Neuroendocrine Tumor Society (NANETS) 2021 neuroendocrine tumor (NET) Medical Symposium, Mei Ka Fong, PharmD, BCOP, said the potential FDA approval of surufatinib could be very important for patients.

Fong said surufatinib targets both the VEGF receptor and the CSF1R receptor, which is a unique mechanism of action.By targeting both receptors, surufatinib targets both the angiogenesis and the tumor tumor's immune evasion, which could make a significant difference in the treatment of NETs.

Related Videos
Pharmacist preparing high-risk chemotherapy
Image Credit: © jarun011 - stock.adobe.com
MP Studio - stock.adobe.com
Image credit: David A Litman | stock.adobe.com
Credit: AkuAku - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.